Abstract:Background: The aim of this study is to evaluate the safety and tumor-control effect of macroscopically surgical resection plus low-dose hemithorax irradiation in this group of patients. Methods: This clinical trial was registered in April 2020 (ChiCTR2000035540). Patients enrolled in this study meet the following criteria: (I) pathologically confirmed thymoma, (II) with pleural dissemination (de-novo or recurrence), (III) removal of all visible lesions by surgical resection, (IV) age between 18 and 75 years. Radiotherapy was carried out 4–6 weeks after surgery via intensity modulated radiotherapy (IMRT) technique. The clinical target volume (CTV) covered the entire ipsilateral pleura and lung structure. A 4–6 mm margin was added beyond CTV to form the planning target volume (PTV). The radiation dose was 14 Gy in 14 fractions. A boost radiation (30 Gy/15 fraction) will be delivered to mediastinal tumor bed if the T stage is beyond T2. Progression-free survival (PFS) and toxicity were recorded as main end-points. Results: From April 2020 to July 2021, a total of 65 patients have been enrolled in this trial. There were 29 male and 36 female patients with the age ranging between 27 and 75 years. The pathological subtypes were A (n=2), AB (n=2), B1 (n=11), B2 (n=23) and B3 (n=27), respectively. Thirty-five patients received previous surgery and developed pleural recurrence before this study, and 27 of them also underwent mediastinal tumor bed radiotherapy (≤50 Gy). The other 30 patients were diagnosed as primary thymoma with pleural dissemination. After surgery, 61 patients completed the hemithorax radiotherapy without severe side effects. The most common adverse events were fatigue, appetite loss and vomiting, and most of them were mild. Two patients suspended treatment at 6 Gy due to fatigue and resumed the therapy after 1–2 weeks of rest. One patient discontinued treatment due to grade 3 thrombocytopenia at 6 Gy, another patient discontinued treatment due to weakness at 8 Gy. After a median follow-up of 18 (10–25) months, 5 (7.7%) patients developed pleural recurrence. By the cut-off time, the disease control rate is 92.3%. Conclusions: Prophylactic entire hemithorax radiotherapy after surgical resection is a safe and effective treatment modality for patients with stage IVa thymoma.

Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: a study of 241 patients.

The long-term outcome and prognostic factors analysis of multimodality treatment for 283 patients with thymoma

Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients.

Role of Adjuvant Radiotherapy for Stage Ii Thymoma after Complete Tumor Resection

AB001. Surgical Resection Followed by Entire Hemithorax Irradiation in Patients with Stage IVa Thymoma: Preliminary Result of a Prospective Phase II Study

The long-term outcome and prognostic analysis of 51 thymic carcinoma patients

Comparison of stages I–II thymoma treated by complete resection with or without adjuvant radiation

Long-Term Follow-Up And Prognostic Factors For Advanced Thymic Carcinoma

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Management and Long-Term Outcomes of Advanced Stage Thymoma in the United States

Analysis of treatment and prognosis of 73 thymic carcinoma patients

Stoical therapy and pathological analysis of thymoma

A Single-Center Analysis of the Treatment and Prognosis of Patients with Thymic Carcinoma

Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database

Prognostic Factor of Completely Resected and Pathologic T3 N0 M0 Thymic Epithelial Tumor

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Investigation of Prognostic Factors in Complete Thymoma Resection Outcomes: A Single-Center Case Series Analysis

The Role of Adjuvant Radiation Therapy in the Treatment of Type B3 Thymoma

Postoperative irradiation in stage II thymomas: is it worth it?—shedding some light in the guidelines' gray zone

Intensity Modulated Radiation Therapy for Pleural Recurrence of Thymoma: A Prospective Phase 2 Study

The Application of Postoperative Chemotherapy in Thymic Tumors and Its Prognostic Effect.